Cyclopharm Limited ( (AU:CYC) ) just unveiled an announcement.
Cyclopharm Limited reported a 4.7% increase in group sales revenue to $27.57 million for the financial year ending December 2024. Despite the revenue growth, the company faced a net loss of $13.2 million, attributed to increased investments in developing new clinical applications for its Technegas™ product, which is expected to provide significant long-term growth opportunities.
More about Cyclopharm Limited
Cyclopharm Limited operates in the healthcare industry, focusing on the development and distribution of medical technologies. The company is known for its Technegas™ product, which is used in nuclear medicine imaging and is exploring new clinical applications for long-term growth.
YTD Price Performance: 25.55%
Average Trading Volume: 110,032
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: A$221.2M
Learn more about CYC stock on TipRanks’ Stock Analysis page.